brainscienceblogs.com

 
we know psychiatry.
Copyright © 2009,
MedWorks Media Global, Los Angeles, CA.
All rights reserved.

Volume 42, Numbers 3 & 4, 2009

VOLUME 42, NUMBER 2, 2009 & VOLUME 42, NUMBER 3, 2009 

RECENTLY PUBLISHED:

Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study
Anthony J. Rothschild, Boadie W. Dunlop, David L. Dunner, Edward S. Friedman, Alan J. Gelenberg, Peter Holland, James H. Kocsis, Susan G. Kornstein, Richard Shelton, Madhukar H. Trivedi, John M. Zajecka, Corey Goldstein, Michael E. Thase, Ron Pedersen, Martin B. Keller

Analysis of Depressive Symptoms in Patients With Major Depressive Disorder Treated With Desvenlafaxine or Placebo
Susan G. Kornstein, Maurizio Fava, Qin Jiang, Karen A. Tourian Drug Disposition & Pharmacokinetics

Efficacy of Omega 3 Fatty Acids in Mood Disorders: A Systematic Review and Metaanalysis
Nina V. Kraguljac, Victor M. Montori, Mani Pavuluri, High S. Chai, Brian S. Wilson, Sencan S. Unal General Psychiatry

A Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder
Rachael Fleurence, Quynh-Van Tran, Rebecca Williamson, Yonghua Jing, Edward Kim, Quynh-Van Tran, Andrei Pikalov, Michael E. Thase Complicated Case Histories

Neonatal Outcomes with the Use of Lamotrigine for Bipolar Disorder in Pregnancy and Breastfeeding: A Case Series and Review of the Literature
Laura Wakil, C. Neill Epperson, Juan Gonzalez, John P. O’Reardon, Deborah R. Kim

Switching to Duloxetine Remits Ziprasidone – Associated Urinary Incontinence and Improves Neuropsychiatric Behavior in Dementia: Possible Relationship of Incontinence to 5HT2 Receptor Blockade
Edward C. Lauterbach, Florence T. Baralatei

Clinical Significance of Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Depression: Synthesis of Recent Data
Mark A. Demitrack, MD, Michael E. Thase, MD

Desvenlafaxineand Venlafaxine Exert Minimal In Vitro Inhibition of Human Cytochrome
P450 and P-glycoprotein Activities

Aram Oganesian, PhD, Adam D. Shilling, PhD, Ruth Young-Sciame, BS, Judy Tran, BS, Adiba Watanyar, BS, Farooq Azam, MS, John Kao, Louis Leung, PhD

Revisiting the Effectiveness of Standard Antidepressants in
Bipolar Disorder: Are Monoamine Oxidase Inhibitors Superior?
Alan G. Mallinger, MD, Ellen Frank, PhD, Michael E. Thase, MD
Michelle M. Barwell, MD, Nancy DiazGranados, MD, David A. Luckenbaugh, MA, David J. Kupfer, MD

Statistical Strategies for Randomized Controlled Clinical Trials to Detect Differential Onset of Action
Andrew C. Leon, PhD

Recent-Onset Schizophrenia and Adolescent Cannabis Use: MRI Evidence for Structural Hyperconnectivity?
Bart D. Peters, MD, Lieuwe de Haan, MD, PhD, Erik-Jan Vlieger, MD, PhD, Charles B. Majoie, MD, PhD, Gerard J. den Heeten, MD, PhD, Don H. Linszen MD, PhD

NEW AND NOTEWORTHY:

Atypical Antipsychotic Drugs and Diabetes Mellitus in the US Food
and Drug Administration Adverse Event Database: A Systematic Bayesian Signal Detection Analysis
By Ross A. Baker, Andrei Pikalov, Quynh-Van Tran, Tatyana Kremenets, Ramin B. Arani,
P. Murali Doraiswamy
Psychopharmacology Bulletin. 2009;42(1):11–31

Bipolar-I Patient Characteristics Associated with Differences in Antimanic Medication Prescribing
By Alisa B. Busch, Richard G. Frank, Gary Sachs, Sharon-Lise T. Normand
Psychopharmacology Bulletin. 2009;42(1):35–49

Neuropsychological Functioning in Patients with Posttraumatic Stress Disorder Following Short-Term Paroxetine Treatment
By Negar Fani, Noriyuki Kitayama, Ali Ashraf, Lai Reed, Nadeem Afzal, Farhan Jawed,
J. Douglas Bremner
Psychopharmacology Bulletin. 2009;42(1):53–68

Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder:An open-label trial
By Jamie D. Feusner, Lauren Kerwin, Sanjaya Saxena, Alexander Bystritsky
Psychopharmacology Bulletin. 2009;42(1):81–93.

Does risperidone Improve Hyperacusia in Children with Autism?
By Ahmad Ghanizadeh
Psychopharmacology Bulletin. 2009;42(1):108–110

Early Symptom Change Prediction of Remission in Depression Treatment
By Martin M. Katz, Adam L. Meyers, Apurva Prakash, Paula J. Gaynor, John P. Houston
Psychopharmacology Bulletin. 2009;42(1):94–107.

An Open-Label Assessment of Aripiprazole in the Treatment of PTSD
By Sophie Robert, Mark B. Hamner, Valerie L. Durkalski, Mary W. Brown, Helen G. Ulmer
Psychopharmacology Bulletin. 2009;42(1):69–80.


While all readers are welcome to explore brainscience.com, this site is designed for mental healthrofessionals with a keen interest in the brain sciences. Many articles are technical, and originate from peer-review journals. Best of luck and good reading. —The Editors

Michael E. Thase, MD, Editor-In-ChiefA Long-Revered Resource in Academia

Published from 1965 until 1999 by the National Institute of Mental Health (NIMH), Psychopharmacology BULLETIN forged its path just as psychiatry itself was embarking on its golden era of treatment breakthroughs and recognition as a valid and independent field of medicine. Within months of MedWorks Media acquiring the rights to the title, the beloved Psychopharmacology BULLETIN was given a facelift, and a powerhouse Editor

The ABCs of Trends: A Mission of Influence

[ndexed in a variety of databases including Index Medicus and PubMed since 1966, Bulletin’s influential name carries with it a certain responsibility to make sense of the trends in medicine for clinicians. With the primary catalyst for cutting-edge remission treatment in anxiety and depression—Michael E. Thase, MD—on board as the new Editor, the Bulletin will cover evidence-based medicine as a section in every issue, along with original works on drug interactions and neuroscientific updates in translational work and imaging. Dr. Thase’s focus is on the future, on broadening the Bulletin’s scope, fostering an ability to engage readers actively, and expanding its already formidable sphere of influence in the field of neuropsychiatry. editorial board masthead